NCT00041327View on ClinicalTrials.gov

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

5 ug/kg/d

BIOLOGICAL

recombinant interferon alfa

9 mU subcutaneously per day for one year

DRUG

Etoposide

50 mg/m2/day continuous 96 hr infusion, days 1-4

DRUG

cyclophosphamide

750 mg/m2 IV on day 5

DRUG

doxorubicin hydrochloride

10 mg/m2/day as a continuous 96-hour infusion days 1-4

DRUG

lamivudine

150 mg bid

DRUG

prednisone

60 mg/m2 given orally days 1-5

DRUG

vincristine sulfate

0.4 mg/m2/day as a 96-hour continuous infusion days 1-4

DRUG

zidovudine

300 mg bid

Trial Locations (3)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

63110

Siteman Cancer Center at Barnes-Jewish Hospital, St Louis

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

AIDS Malignancy Consortium

NETWORK

NCT00041327 - Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma | Biotech Hunter | Biotech Hunter